Non-Hodgkin's lymphoma is a heterogeneous group of lymphoproliferative malignancies.
It is the most common hematologic cancer.
The most common subtypes are the diffuse large B-cell and follicular lymphoma. The subtypes are based on the malignant cell's morphology, genetic features, immunohistological characteristics, and stage of maturation.

Follow Up

  • Prognosis depends on the patient’s age, performance status, serum LDH, clinical disease stage & presence or absence of extranodal site involvement
    • >2 prognostic factors increases the chances for recurrence and decreases overall survival
  • Patients undergoing Alemtuzumab treatment should be monitored for cytomegalovirus (CMV) reactivation using quantitative polymerase chain reaction (PCR) assay every 2-3 weeks during therapy & every 2 month after completion of treatment

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Editor's Recommendations
Most Read Articles
04 Dec 2017
Management of locally advanced hepatocellular carcinoma aims to improve survival and to maintain the quality of life of patients, with less likelihood of cure due to the advanced nature of disease. Upon diagnosis of the severity of liver cancer, offering appropriate and proven treatment options is important to extend the survival of these patients.
Dr Joslyn Ngu, 04 Dec 2017

Genetic testing has changed the landscape of lung cancer and every patient needs to undergo testing, says a specialist.

Dr Joslyn Ngu, 04 Dec 2017

Incorporating polygenic risk scores based on 18 SNPs (single nucleotide polymorphisms) into risk stratification for breast cancer will improve screening results, says an expert.

Tristan Manalac, 4 days ago
Adherence to risk management procedures following genetic testing for breast cancer-related mutations is high, a recent Singapore study has shown. However, targeted approaches may be needed to reduce further risk of ovarian cancer.